Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE versus NETROMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE versus NETROMYCIN.
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE vs NETROMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin and polymyxin B sulfates are aminoglycoside and polypeptide antibiotics, respectively, that inhibit bacterial protein synthesis and disrupt bacterial cell membrane integrity. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Netromycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis in bacteria.
Ophthalmic: 1-2 drops in affected eye(s) every 3-4 hours; severe infections: 1-2 drops every 1-2 hours, then taper. Otic: 3-4 drops in affected ear(s) 3-4 times daily.
4-6 mg/kg IV once daily for serious infections; 1.5-2 mg/kg IV every 8 hours for gram-negative infections. Administered as intravenous infusion over 30-60 minutes.
None Documented
None Documented
Neomycin: 2-3 hours (IM/IV, if absorbed); Polymyxin B: 6-7 hours; Dexamethasone: 3-4.5 hours. Clinically, neomycin's half-life is not relevant due to minimal absorption; polymyxin B prolonged in renal impairment; dexamethasone CNS effect lasts > half-life.
Terminal elimination half-life is 2-3 hours in adults with normal renal function, but may extend to 24-48 hours in patients with impaired renal function.
Neomycin: ~99% of oral dose eliminated unchanged in feces; <1% absorbed renally excreted. Polymyxin B: ~60% renal elimination of absorbed fraction; remainder non-renal via biliary/fecal. Dexamethasone: ~65% renal as metabolites, <10% unchanged; ~35% fecal.
Renal excretion of unchanged drug accounts for 80-90% of elimination via glomerular filtration; biliary/fecal elimination is minimal (<5%).
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic